1. Introduction {#s0005}
===============

Neuroticism is a longitudinally and culturally robust measure of emotional stability that emerges as a key dimension in almost all personality systems since proposed by Eysenck ([@bb0075]). The various manifestations of neuroticism in different assessments have been shown to exhibit considerable overlap ([@bb0015; @bb0210; @bb0280]) and the trait is quite stable over many years ([@bb0270]). Neuroticism can be detected within a variety of different social strata and cultures ([@bb0070]) and may even be recognized in the behavior of other, less complex, organisms ([@bb0105; @bb0110]).

Neuroticism is important in the study of human psychiatric disease because of evidence that it reflects predisposition to experiencing symptoms of anxiety and depression. High neuroticism scores are robustly associated with an increased risk for depression ([@bb0025; @bb0130; @bb0145; @bb0155; @bb0265]), and experience of a depressive episode yields an elevation in neuroticism which persists after post-recovery (i.e., a scar effect) ([@bb0225]). Neuroticism is known to be a strong risk factor for the lifetime prevalence of major depressive disorder (MDD) ([@bb0010; @bb0130; @bb0230; @bb0235]).

Work in European and US populations indicates that the association between MDD and neuroticism is in part mediated by a common genetic susceptibility ([@bb0085]) which also contributes to the correlation between MDD and anxiety disorders ([@bb0115; @bb0120; @bb0140; @bb0165]). While evidence indicates that the features of neuroticism are similar in different cultures and countries ([@bb0205]), it is not clear whether the relation between neuroticism and MDD is present in non-Western populations.

In this paper, we report the results from a large-scale clinical study of Chinese Han women with recurrent MDD and matched controls. We aimed to evaluate three hypotheses: (1) neuroticism is related strongly to lifetime prevalence of MDD; (2) neuroticism increases the likelihood of comorbid disorders; (3) neuroticism is associated with the age at onset, number and maximal duration of episodes, and the pattern of reported symptoms.

2. Method {#s0010}
=========

2.1. Subjects {#s0015}
-------------

Data for the present study draws upon the ongoing China, Oxford and VCU Experimental Research on Genetic Epidemiology (CONVERGE) study of MDD. Analyses were based on a total of 1970 cases recruited from 53 provincial mental health centers and psychiatric departments of general medical hospitals in 41 cities in 19 provinces and four central cities: Beijng, Shanghai, Tianjin and Chongqing and 2597 controls who were recruited from patients undergoing minor surgical procedures at general hospitals or from local community centers. All cases and controls were female and had four Han Chinese grandparents. Cases and controls were excluded if they had a pre-existing history of bipolar disorder, any type of psychosis or mental retardation. Cases were aged between 30 and 60, had two or more episodes of MDD, with the first episode occurring between 14 and 50 and had not abused drug or alcohol before the first episode of MDD. Controls were chosen to match the region of origin of cases, were aged between 40 and 60, had never experienced an episode of MDD and were not blood relatives of cases. An older minimal age of controls was used to reduce the chances that they might have a subsequent first onset of MDD. The mean age (and SD) of cases and controls in the dataset was respectively 45.1 (8.8) and 47.7 (5.5).

All subjects were interviewed using a computerized assessment system, which lasted on average 2 h for a case and 1 h for a control. All interviewers were trained by the CONVERGE team for a minimum of one week in the use of the interview. The interview includes assessment of psychopathology, demographic and personal characteristics, and psychosocial functioning. Interviews were tape-recorded and a proportion of them were listened to by the trained editors who provided feedback on the quality of the interviews.

The study protocol was approved centrally by the Ethical Review Board of Oxford University and the ethics committee in participating hospitals in China.

2.2. Measures {#s0020}
-------------

The diagnoses of depressive (dysthymia and MDD) and anxiety disorders (generalized anxiety disorder, panic disorder with or without agoraphobia) were established with the Composite International Diagnostic Interview (CIDI) (WHO lifetime version 2.1; Chinese version), which classifies diagnoses according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria ([@bb0020]). The interview was originally translated into Mandarin by a team of psychiatrists in Psychiatry department of Huashan Hospital of Fudan University, Shanghai Mental Health Center of Jiao Tong University, School of Medicine and Psychiatry department of Tongji Hospital of Tongji University Shanghai Mental Health Centre with the translation reviewed and modified by members of the CONVERGE team. Phobias, divided into five subtypes (animal, situational, social and blood-injury, and agoraphobia) were diagnosed using an adaptation of DSM-III criteria requiring one or more unreasonable fears, including fears of different animals, social phobia and agoraphobia that objectively interfered with the respondent\'s life. The section on the assessment of phobias was translated by the CONVERGE team from the interview used in the Virginia Adult Twin Study of Psychiatric and Substance Use Disorders (VATSPUD) ([@bb0150]).

Additional information using instruments employed from VATSPSUD, translated and reviewed for accuracy by members of the CONVERGE team, was collected on neuroticism.

Neuroticism was measured with the 23-item Eysenck Personality Questionnaire([@bb0075]), which was also an established instrument for measuring neuroticism.

Both the case and control interview were fully computerized into a bilingual system of Mandarin and English developed in house in Oxford, and called SysQ. Skip patterns were built into SysQ. Interviews were administered by trained interviewers and entered offline in real time onto SysQ, which was installed in the laptops. Once an interview was completed, a backup file containing all the previously entered interview data could be generated with database compatible format. The backup files together with an audio recording of the entire interview were uploaded to a designated server currently maintained in Beijing by a service provider. All the uploaded files in the Beijing server were then transferred to an Oxford server quarterly.

2.3. Statistical analysis {#s0025}
-------------------------

We performed logistic regression analyses to estimate the association of neuroticism with MDD and comorbid disorders (dysthymia, generalized anxiety disorder, panic disorder, agoraphobia,social phobia, animal phobia, situational phobia, and blood-injury phobia).MDD and comorbid disorders were coded as binary (1 = present, 0 = absent). Analyses of the relationship between neuroticism and the risk for lifetime MDD and comorbid disorders were conducted by binary logistic regression using SPSS version 17.0. Neuroticism scores were standardized so that the odds ratio (OR) reflected the alteration in the risk of MDD with every increase of 1 SD in neuroticism.

3. Results {#s0030}
==========

We obtained neuroticism scores on 1915 women with recurrent MDD and 2275 controls. The distribution of neuroticism scores is strikingly different in the two groups, "J" shaped in the controls and approximating a normal distribution in the cases ([Fig. 1](#f0005){ref-type="fig"}). The mean neuroticism score for cases is 12.7 (median 13) and the mean neuroticism score for controls is 3.6 (median 2). The difference between the two distributions is highly significant (t \> 58, permutation derived P value \< 0.0001).

[Table 1](#t0005){ref-type="table"} shows the odds ratios from the logistic regression analyses for MDD and comorbid disorders. In our full case--control sample, we found that increasing the neuroticism score by one standard deviation (s.d.) carries an odds ratio for MDD of 1.37. In our case sample, we also found that higher neuroticism scores significantly increased the risk of all comorbid disorders examined. For each s.d. increase in neuroticism, the highest risk increase was for generalized anxiety disorder (OR = 1.13) and the lowest was for phobia (OR = 1.06).

When we examined cases of MDD we found that higher neuroticism scores significantly increased the risk for the number of comorbid disorders (OR = 1.13), the number of MDD episodes (OR = 1.07), and the number of depressive symptoms (OR = 1.08) ([Table 2](#t0010){ref-type="table"}). Using linear regression, we found a highly significant relationship between neuroticism and the age at onset of MDD (P value \< 1 × 10^− 14^); neuroticism explained 3% of the variance in age of onset. Neuroticism scores were also modestly related to the maximal duration of episodes (P value = 0.004) explaining \~ 0.5% of the variance.

4. Discussion {#s0035}
=============

We have examined the relationship between the personality trait of neuroticism and MDD in a large clinically ascertained sample of Chinese female patients with recurrent MDD. Our study has three major findings. First, neuroticism scores were strongly related to the lifetime prevalence of MDD. Second, an increase in neuroticism scores increases the likelihood of comorbid disorders in those with MDD. Third, in those affected with MDD, neuroticism scores are associated with several important clinical features of MDD. Higher scores predicted a younger age of onset, more episodes of depression, a higher symptom score and a longer maximal duration of an MDD episode. These findings establish neuroticism as an important predictor of the onset and severity of MDD in our sample.

To our knowledge this is the first study of neuroticism in Chinese female patients with MDD. Previous work among adolescents and University students in China has shown a relationship between personality features and depressive symptoms ([@bb0190; @bb0250; @bb0260]), but no one has documented the effect of neuroticism on the clinical features of MDD.

Our findings replicate the results obtained in clinical populations in Europe and US in a number of ways. We find that the effect of neuroticism on MDD is of a similar magnitude to that reported elsewhere in the world. Typically Western studies estimate the OR of neuroticism to be about 1.5, where the OR reflects the alteration in risk of MDD with each increase of 1 standard deviation in the neuroticism score ([@bb0160]). Our estimate is only slightly less: 1.37. In Western studies, neuroticism has been shown to account for about a third of the comorbidity with internalizing disorders (which include anxiety and depression) ([@bb0180]) and to correlate with the severity of depression (indexed by the duration and number of episodes) ([@bb0010; @bb0065; @bb0240]). We find that in Chinese patients high neuroticism scores also predispose to higher comorbidity and scores correlate with disease severity. Previous research found that neuroticism accounted for a significant part of the lifetime comorbidity of common psychiatric disorders (internalizing disorders and externalizing disorders) and suggests neuroticism as a potential general underlying vulnerability factor for psychopathology ([@bb0055; @bb0180; @bb0185; @bb0245]). As a cross sectional analysis, our results showed that elevated neuroticism scores were associated with lifetime comorbidity.

Neuroticism scores in our sample differ from those reported in the West: most strikingly, the mean score is much lower. Studies in European community acquired populations report mean neuroticism scores with a distribution approximating normality centered around a mean of 10 ([@bb0070; @bb0200]); we find a mean of 3.6 in the community acquired sample of Chinese women, and a highly skewed distribution. The apparent lower levels of neuroticism in our sample are potentially important, as they may be related to the lower rates of MDD in China compared to the West: the 12-month prevalence of MD is approximately 7% in the US ([@bb0175]) and 2% in China ([@bb0220]).

Personality factors, including neuroticism, are known to vary across cultures, and there are varying, sometimes conflicting, explanations offered ([@bb0005; @bb0030; @bb0135; @bb0195]). However explaining cross-cultural variation with respect to China is particularly difficult because there has been relatively little research into personality (psychology was only reinstated as an approved discipline in the PRC in the 1980s).

Two points deserve note. First personality factors in China may not be identical to those observed in the West. While the majority of work since the 1980s has relied on measures developed in Western countries ([@bb0040; @bb0275]), since the development and use of indigenous personality inventories, such as the Chinese Personality Assessment Inventory ([@bb0045]), it has been argued that a different personality model (six-factor model) is superior to the model commonly found in the West (five factor model) ([@bb0050]). Second, cultural variation in neuroticism scores may be due to methodological differences between studies ([@bb0100; @bb0255]). For example the meaning of an item may alter subtly after translation, and the context in which the test is administered may bias responses, a potentially important factor in our work. Even though subjects fill in the questionnaire themselves, it is likely that their responses are affected by the respect Chinese traditionally hold for people in authority, such as doctors. However this factor would not explain the difference in neuroticism scores seen between patients and controls.

The results of our study should be interpreted in the context of three potential methodological limitations. First, all cases in our study were selected from a clinical sample. Our results may not apply to MDD in community-acquired samples. Second, the sample was limited to Chinese Han women, so the results may not generalize to men and to individuals from other ethnic groups. Third, we cannot, in this sample, gain direct insight into the causal relationship between neuroticism and MDD as we assessed in a single interview the level of neuroticism and the lifetime history of MDD.

The results that we observe probably reflect several mechanisms. Most important is probably the fact that neuroticism reflects an underlying liability to MDD ([@bb0035; @bb0090; @bb0155; @bb0215]). At least two other mechanisms likely play a role: a direct effect of MDD on the level of neuroticism for those currently in an episode ("state" effect) ([@bb0060; @bb0090; @bb0095; @bb0125; @bb0155; @bb0170]) and a long-term effect of prior depressive episodes on neuroticism ("scar" effect) ([@bb0090; @bb0095; @bb0155; @bb0225]).
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###### 

Neuroticism as a predictor for MDD and comorbid disorders.

                     OR     95%CI          p-value
  ------------------ ------ -------------- -----------------
  MDD                1.37   1.35 to 1.40   2.2 × 10^− 263^
  MD + GAD           1.13   1.11 to 1.15   3.4 × 10^− 34^
  MD + panic         1.09   1.06 to 1.12   3.1 × 10^− 9^
  MD + dysthymia     1.12   1.10 to 1.15   8.2 × 10^− 22^
  MD + phobia        1.06   1.04 to 1.08   4.2 × 10^− 11^
  MD + agoraphobia   1.08   1.06 to 1.10   8.3 × 10^− 17^
  MD + social        1.07   1.05 to 1.09   4.8 × 10^− 14^
  MD + Animal        1.03   1.02 to 1.05   4.0 × 10^− 5^
  MD + situational   1.06   1.04 to 1.07   1.4 × 10^− 10^
  MD + blood         1.05   1.04 to 1.07   7.9 × 10^− 10^

Odds ratios (OR) with 95% confidence intervals (95% CI) and their statistical significance (p-value) are reported. An odds ratio of \> 1 represents the increase in risk of MDD and comorbidity associated with each standard deviation (sd) increase in the score of the neuroticism. An odds ratio of \< 1 represents the decrease in risk of MDD and comorbidity associated with each sd increase in neuroticism score.

###### 

Neuroticism as predictor of the number of comorbid disorders, the pattern of reported depressive symptoms, and number of episodes of MDD.

                                OR     95%CI          p-value
  ----------------------------- ------ -------------- ----------------
  Number of comorbid diseases   1.13   1.11 to 1.15   2.4 × 10^− 55^
  Number of MDD symptoms        1.08   1.07 to 1.10   1.3 × 10^− 25^
  Number of melancholia         1.00   0.99 to 1.02   0.676
  Number of MDD episodes        1.07   1.04 to 1.10   5.4 × 10^− 6^

Odds ratios (OR) with 95% confidence intervals (95%CI) and their statistical significance (p-value) are reported. An odds ratio of \> 1 represents the increase in risk of MDD and comorbidity associated with each standard deviation increase in the score of the neuroticism. An odds ratio of \< 1 represents the decrease in risk of MDD and comorbidity associated with each standard deviation increase in neuroticism score.
